---
title: "Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone | NXTS Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286248783.md"
description: "Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone | NXTS Stock News"
datetime: "2026-05-13T03:10:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286248783.md)
  - [en](https://longbridge.com/en/news/286248783.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286248783.md)
---

# Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone | NXTS Stock News

Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone | NXTS Stock News

### Related Stocks

- [NXTS.US](https://longbridge.com/en/quote/NXTS.US.md)

## Related News & Research

- [NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones | NTHI Stock News](https://longbridge.com/en/news/286931037.md)
- [VALION BIO BRIEFS SENIOR DEPARTMENT OF WAR AND BARDA OFFICIALS IN JOINT ENGAGEMENT ON ENTOLIMOD FOR ACUTE RADIATION SYNDROME | VBIO Stock News](https://longbridge.com/en/news/286964504.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)
- [Belite Bio Q1 Net Loss Expands; Plans To Complete Rolling NDA Submission For Tinlarebant In Q2 2026](https://longbridge.com/en/news/287055320.md)